Phase II Study of Hydroxyurea for Unresectable Meningioma
Phase II Study of Hydroxyurea for Unresectable Meningioma
RATIONALE: Drugs used in chemotherapy such as hydroxyurea use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: This phase II trial is studying how well hydroxyurea works in treating patients with unresectable benign meningioma.
OBJECTIVES:
OUTLINE: Patients receive oral hydroxyurea twice daily for 2 years in the absence of disease progression or unacceptable toxicity.
Patients are followed at 3 months, 6 months, and then every 6 months for 3 years.
PROJECTED ACCRUAL: A total of 38 patients will be accrued for this study within 13 months.
DISEASE CHARACTERISTICS:
PATIENT CHARACTERISTICS:
Age:
Performance status:
Life expectancy:
Hematopoietic:
Hepatic:
Renal:
Other:
PRIOR CONCURRENT THERAPY:
Biologic therapy:
Chemotherapy:
Endocrine therapy:
Radiotherapy:
Surgery:
Fairbanks, Alaska 99701, United States
Little Rock, Arkansas 72205, United States
Aurora, Colorado 80010, United States
Wichita, Kansas 67214, United States
New Orleans, Louisiana 70140-1015, United States
Fridley, Minnesota 55432-2799, United States
Minneapolis, Minnesota 55407, United States
Robbinsdale, Minnesota 55422-2900, United States
Newark, Ohio 43055-2899, United States
Anderson, South Carolina 29621, United States
Sioux Falls, South Dakota 57104, United States
Sioux Falls, South Dakota 57105-1080, United States
Auburn, Washington 98001-4908, United States
Kirkland, Washington 98034-3013, United States